Replimune Group, Inc.

DB:7R8 Stock Report

Market Cap: €931.2m

Replimune Group Valuation

Is 7R8 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 7R8 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 7R8 (€13.4) is trading below our estimate of fair value (€27.8)

Significantly Below Fair Value: 7R8 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 7R8?

Key metric: As 7R8 is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 7R8. This is calculated by dividing 7R8's market cap by their current book value.
What is 7R8's PB Ratio?
PB Ratio2.5x
BookUS$381.46m
Market CapUS$983.84m

Price to Book Ratio vs Peers

How does 7R8's PB Ratio compare to its peers?

The above table shows the PB ratio for 7R8 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average1.9x
FYB Formycon
1.5x31.5%€857.2m
BIO3 Biotest
2x29.3%€1.3b
HPHA Heidelberg Pharma
3x-33.0%€105.8m
2INV 2invest
1xn/a€62.7m
7R8 Replimune Group
2.5x21.0%€983.8m

Price-To-Book vs Peers: 7R8 is expensive based on its Price-To-Book Ratio (2.5x) compared to the peer average (1.9x).

Price to Book Ratio vs Industry

How does 7R8's PB Ratio compare vs other companies in the DE Biotechs Industry?

3 CompaniesPrice / BookEstimated GrowthMarket Cap
V9Z Aceragen
0.1xn/aUS$3.12m
V9Z Aceragen
0.1xn/aUS$2.18m
O7P NeuBase Therapeutics
0.1xn/aUS$1.39m
No more companies available in this PB range
7R8 2.5xIndustry Avg. 2.4xNo. of Companies3PB00.61.21.82.43+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: 7R8 is expensive based on its Price-To-Book Ratio (2.5x) compared to the European Biotechs industry average (2.4x).

Price to Book Ratio vs Fair Ratio

What is 7R8's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

7R8 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio2.5x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 7R8's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 7R8 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€13.40
€15.84
+18.2%
7.4%€17.29€13.44n/a8
Nov ’25€10.60
€14.31
+35.0%
9.7%€15.70€12.01n/a8
Oct ’25€9.75
€14.02
+43.8%
9.5%€15.21€11.63n/a9
Sep ’25€9.85
€13.31
+35.1%
12.0%€15.20€10.73n/a9
Aug ’25n/a
€13.27
0%
16.8%€15.74€9.26n/a9
Jul ’25n/a
€13.27
0%
16.8%€15.74€9.26n/a9
Jun ’25€4.62
€12.53
+171.1%
18.1%€17.56€9.24n/a9
May ’25€6.05
€12.53
+107.1%
18.1%€17.56€9.24n/a9
Apr ’25€7.50
€12.53
+67.0%
18.1%€17.56€9.24n/a9
Mar ’25€7.80
€12.53
+60.6%
18.1%€17.56€9.24n/a9
Feb ’25€7.05
€12.08
+71.3%
19.5%€17.65€9.29n/a9
Jan ’25n/a
€12.08
0%
19.5%€17.65€9.29n/a9
Dec ’24€10.10
€44.50
+340.6%
22.3%€64.30€29.39n/a9
Nov ’24€13.50
€45.26
+235.3%
20.9%€64.37€30.35€10.609
Oct ’24€15.30
€45.26
+195.8%
20.9%€64.37€30.35€9.759
Sep ’24€18.50
€45.26
+144.7%
20.9%€64.37€30.35€9.859
Aug ’24€18.90
€47.19
+149.7%
18.2%€63.64€30.00n/a10
Jul ’24n/a
€47.41
0%
18.2%€63.95€30.15n/a10
Jun ’24€17.50
€46.79
+167.4%
20.4%€64.73€30.52€4.6210
May ’24€15.00
€46.39
+209.2%
20.1%€64.04€31.11€6.0510
Apr ’24€15.80
€48.47
+206.7%
20.3%€65.95€32.03€7.509
Mar ’24€20.20
€49.39
+144.5%
19.4%€66.35€32.23€7.8010
Feb ’24n/a
€48.55
0%
20.9%€66.00€32.06€7.0510
Jan ’24n/a
€47.32
0%
21.7%€65.52€31.82n/a9
Dec ’23€19.30
€44.47
+130.4%
18.8%€59.56€29.78€10.1010
Nov ’23€18.10
€47.19
+160.7%
21.1%€61.69€30.84€13.5010

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Teva Pharmaceutical Industries

US$18.8b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEV

US$15.65

7D

-3.7%

1Y

76.2%

Collegium Pharmaceutical

US$1.0b

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

354

US$29.60

7D

5.7%

1Y

27.6%

Pharming Group

€491.5m

A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.

PHGN

€0.70

7D

-0.7%

1Y

-34.1%